Halozyme Therapeutics Inc (NASDAQ: HALO) stock enjoyed a major increase of 10.0% on 11/7/23. The shares closed at $38.80. The stock has performed in line with the market over the last nine months and has risen 14.1% during the last week.
Current PriceTarget Research Rating
HALO’s future returns on capital are forecasted to be above the cost of capital. Accordingly, the company is expected to continue to be a major Value Builder.
Halozyme Therapeutics has a current Value Trend Rating of A (Highest Rating). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Halozyme Therapeutics has a neutral Power Rating of 51 but a very high Appreciation Score of 97, triggering the Highest Value Trend Rating.
Rating Review
In light of this very positive price change we are reviewing our current Overall Rating of A. This review will be completed in the next several days.
Be the first to comment